INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Submission of Matters to a Vote of Security Holders

INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security
Holders.

The following actions were taken at the Annual Meeting of
Stockholders of Incyte Corporation (the Company):

1. The following Directors were elected:

		For		Withheld		BrokerNon- Votes
Julian C. Baker		170,291,792		3,492,653		12,390,808
Jean-Jacques Bienaim		162,495,137		11,289,308		12,390,808
Paul A. Brooke		170,574,124		3,210,321		12,390,808
Paul J. Clancy		172,127,317		1,657,128		12,390,808
Wendy L. Dixon		167,451,838		6,332,607		12,390,808
Paul A. Friedman		159,543,671		14,240,774		12,390,808
Herv Hoppenot		170,047,703		3,736,742		12,390,808

2. The compensation of the Companys named executive officers was
approved, on a non-binding advisory basis.

For		Against		Abstain		BrokerNon-Votes
169,371,921		4,273,231		139,293		12,390,808

3. The stockholders recommended, on a non-binding advisory basis,
that future non-binding advisory stockholder votes on the
compensation of the Companys named executive officers should
occur every year.

EveryYear		Every2Years		Every3Years		Abstain
159,897,364		373,397		13,360,793		152,891

Based on these results and in line with the Companys Board of
Directors recommendation, the Company will hold a non-binding
advisory vote on the compensation of the Companys named executive
officers every year, until the next non-binding advisory vote on
the frequency of future advisory votes on the compensation of the
Companys named executive officers. An advisory vote on the
frequency of future advisory votes on the compensation paid to
the Companys named executive officers is required to be held at
least once every six years.

4. The appointment of Ernst Young LLP as the Companys independent
registered public accounting firm for the 2017 fiscal year was
ratified.

About INCYTE CORPORATION (NASDAQ:INCY)
Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company’s pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company’s second oral JAK1 and JAK2 inhibitor is baricitinib. INCYTE CORPORATION (NASDAQ:INCY) Recent Trading Information
INCYTE CORPORATION (NASDAQ:INCY) closed its last trading session down -3.89 at 130.49 with 2,366,454 shares trading hands.